HDAC9 and breast carcinoma: Accumulating evidence indicates that enhanced activation of oncogenic molecular signaling pathways such CDK4/6, HDAC, Src, IGFR-1, FGFR and PI3K/Akt in breast cancer cells plays a significant role in developing therapy resistance.